Tim Richardson

13PUBLICATIONS
66CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Mar 31, 2026
IPSS-M downstaging before transplantation does not improve the prognosis of patients with myelodysplastic neoplasms.

T Richardson, D Schütte, P Gödel

|Feb 13, 2026
Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy.

Jan H Frenking, Christine Riedhammer, Thomas Hielscher

|Nov 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.

Tim Richardson, Elias Mai, Ekaterina Menis

|Sep 02, 2025
Early Free Light-Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA-Directed CAR-T Cells.

Tim Richardson, Hishan Tharmaseelan, Guido Kobbe

|Jul 11, 2025
Sequential BCMA CAR T-cell therapy in refractory multiple myeloma.

Tim Richardson, Udo Holtick, Jan-Hendrik Frenking

|Feb 21, 2025
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody.

Till Braun, Michael Rade, Maximilian Merz

Pageof 3

Frequent Collaborators

4 joint publications

Michael Hallek

3 joint publications

Udo Holtick

3 joint publications

Christoph Scheid

2 joint publications

Daniel Schütte